PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate ...

Integra LifeSciences Holdings Corporation (IART) is successfully broadening its international footprint through certain key developments on the overseas front. The company also sees healthy demand for its industry-leading products within the Codman Specialty Surgical (CSS) segment. A strong emphasis on portfolio optimization has steadily ramped up its research and development (R&D) spend, which is highly promising. Meanwhile, macroeconomic headwinds and a negative solvency remain concerns for Integra’s oper ...

Core Viewpoint - Grabar Law Office is investigating potential breaches of fiduciary duties by the Board of Directors of Integra LifeSciences Holdings Corp. [1] Group 1: Shareholder Actions - Current shareholders who held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms and the return of funds spent on litigation [2][4] - Shareholders can also pursue a court-approved incentive award at no cost [2][4] Group 2: Securities Fraud Allegations - A securities fraud class action complaint alleges that Integra's officers and directors misrepresented the company's growth prospects for SurgiMend, claiming FDA approval for post-mastectomy reconstruction [3] - On May 23, 2023, Integra announced a recall of all products manufactured at its Boston Facility from March 1, 2018, to May 22, 2023, due to deviations from good manufacturing practices [3] - The recall was attributed to unsafe levels of bacterial endotoxins in products, leading to a revised revenue guidance for Q2 2023 and an expected $22 million impairment from inventory write-off [3]

PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.c ...

PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Mojdeh Poul, chief executive officer and Lea Knight, chief financial officer will present at the 35th Annual Oppenheimer Healthcare MedTech & Services Conference on March 17, 2025 at 10:00am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.co ...

Integra LifeSciences ( IART ) has had a miserable time of it since the mid-2023 announcement of quality control issues at the company’s Boston plant that not only sapped important growth drivers in the Tissue Technologies business but also necessitatedAnalyst’s Disclosure: I/we have a beneficial long position in the shares of SOLV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than fr ...

Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 97 cents for the fourth quarter of 2024, which surpassed the Zacks Consensus Estimate by 14.1%. The metric increased 9% year over year.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustment excludes the impact of certain non-recurring charges like structural optimization charges, divestiture, acquisition and integration-related charges, and EU Medical Device Regulation charges, amon ...

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corp. (NASDAQ: IART) on behalf of long-term stockholders following a class action complaint that was filed against Integra on September 12, 2023 with a Class Period from March 11, 2019 to May 22, 2023. Our investigation concerns whether the board of directors of Integra have breached their fiduciary duties to the ...

Business Segments and Growth - Integra LifeSciences operates in two reportable segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT), with CSS accounting for approximately two-thirds of total revenue[19]. - The acquisition of Acclarent in April 2024 positions Integra as a leading provider in ENT products, expanding its market reach and innovation potential[28]. - Integra's international expansion includes new product launches in Europe and Asia, such as MicroMatrix® and Certas Plus® Programmable Valve[26][27]. - The neurosurgical business has seen growth driven by geographic expansion and new product registrations in markets such as China, Japan, and Europe, with expectations for continued growth in the near-to-long term[47]. - The company has significant manufacturing and distribution sites in North America, Europe, China, and Japan, indicating a global operational footprint[138]. Product Development and Innovation - The company anticipates PMA approval for DuraSorb in 2026, following the completion of a clinical study and operationalization of the Braintree facility expected in the first half of 2026[23][45]. - In 2024, Integra launched MicroMatrix® Flex in the U.S., enhancing wound management capabilities[24]. - Integra's R&D strategy focuses on innovative solutions for unmet surgical needs, with significant investments in regenerative technologies and clinical studies[41][42]. - The CUSA® Clarity platform has been updated with new ultrasonic handpiece and electrosurgical capabilities, including a successful commercial launch of a single-sided bone tip in early 2023[48]. - The Aurora Surgiscope, a single-use medical device for cranial surgery, received 510(k) clearance from the FDA in Q4 2023, indicating progress in innovation[50]. Regulatory Environment and Compliance - The regulatory environment is stringent, with extensive FDA regulations governing the introduction and marketing of medical devices, impacting operational timelines and costs[63]. - The FDA requires 510(k) clearance or PMA for medical devices, with Class II and III devices needing pre-market notification or approval[72]. - Compliance with patient and data privacy laws, as well as environmental regulations, is essential for maintaining operational integrity and market access[62]. - The company is subject to various healthcare regulations, including the U.S. federal Anti-Kickback Statute, which prohibits certain remuneration practices that could influence healthcare decisions[94]. - The EU MDR, effective from May 26, 2021, introduces stricter regulations for medical devices in the EEA, replacing the previous EU MDD[80]. Financial Performance and Market Challenges - Revenues typically peak in the fourth quarter due to increased hospital purchases coinciding with budget cycles, with Q1 usually showing lower revenues[59]. - Legislative changes, such as the Budget Control Act of 2011, have resulted in automatic reductions of Medicare payments, affecting revenue[90]. - The company faces potential challenges in market acceptance due to reimbursement policies from government and private payors[87]. - The company faces heightened governmental scrutiny regarding product pricing, which could lead to reduced demand for its products due to potential limitations on coverage and reimbursement[92]. - The company may incur substantial costs to comply with future environmental, health, and safety laws and regulations, impacting its financial condition[100]. Workforce and Corporate Culture - As of December 31, 2024, the company had approximately 4,396 regular full and part-time employees, with 70% located in the United States, 20% in Europe, 9% in Asia Pacific, and 1% in Latin America and Canada[110]. - The company maintained seven employee-led Employee Resource Groups (ERGs) in fiscal year 2024, focusing on career development and networking opportunities[111]. - The company is committed to pay equity and regularly conducts pay equity analyses to adjust compensation as necessary[113]. - The company emphasizes talent development through various learning and development programs, which are critical for employee satisfaction and retention[115]. - The company conducts annual global engagement pulse surveys to gather employee feedback and improve workplace satisfaction[117]. Cybersecurity and Data Privacy - The company is increasingly dependent on sophisticated information technology, and any significant disruptions could have a material adverse effect on its business[204]. - Cybersecurity risks are heightened due to remote work, which may create vulnerabilities for cybercriminals to exploit[206]. - The company maintains a comprehensive cybersecurity program, including regular evaluations and collaboration with third-party cybersecurity services[210]. - Compliance with evolving data privacy laws, such as GDPR and HIPAA, may require significant changes to products and incur additional costs[208]. - The incident response team is generally led by the CIO and includes IT and legal personnel, with escalation protocols to update the Board and senior management on significant incidents[214]. Acquisitions and Strategic Growth - The company has acquired two businesses between January 1, 2022, and December 31, 2024, at a total cost of approximately $329.3 million, including Surgical Innovation Associates, Inc. for $51.5 million and Acclarent, Inc. for $277.8 million[133]. - The company is currently engaged in evaluations of potential acquisitions and is in various stages of discussion regarding possible acquisitions, which could significantly impact future growth[135]. - The company’s future profitability will depend on its ability to develop resources to adapt to new products or business areas acquired through acquisitions[135]. - The company may face impairments or other charges related to goodwill and indefinite-lived intangible assets, which could materially affect its financial statements[147]. - The company may experience difficulties in growing sales in new international markets due to customer acceptance and regulatory restrictions[140]. Supply Chain and Manufacturing - The company maintains long-term supply contracts with suppliers to ensure the availability of raw materials, which is critical for uninterrupted production[55]. - The company faces challenges in replacing sole-source suppliers for key components and raw materials, which could disrupt manufacturing capabilities[154]. - The company anticipates increased costs and potential supply chain disruptions due to global economic factors, including inflation and geopolitical events[158]. - The transition of manufacturing activities to the Braintree facility may not realize anticipated benefits due to unforeseen challenges[173]. - The company is exposed to product liability claims, which may exceed insurance coverage or be excluded from coverage[164].

Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements. Some of these forward-looking statements may contain words like "will," "believe," "may," "could," "would," "might," "possible," " ...